Clinical Trial Update: Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma [NA]

View source ↗

Summary

This document describes a clinical trial evaluating ACT-001, an allogeneic anti-BCMA/GPRC5D bispecific CAR-NK cell therapy, for relapsed or refractory multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ACT-001

Snippet

Sponsor: RenJi Hospital | Conditions: Multiple Myeloma | NA | Status: NOT_YET_RECRUITING